(IBHE) iShares iBonds 2025 Term - Ratings and Ratios

Exchange: BATS • Country: USA • Currency: USD • Type: Etf • ISIN: US46435U1685

High-Yield, Investment-Grade, 2025 Maturity, Fixed-Rate, Corporate Bonds

Description: IBHE iShares iBonds 2025 Term

The iShares iBonds 2025 Term High Yield and Income ETF (IBHE) is a targeted maturity ETF that focuses on investing in a portfolio of high-yield corporate bonds with maturities between January 1, 2025, and December 15, 2025. The funds investment strategy is designed to provide a predictable income stream and return of principal at maturity.

The underlying index tracks U.S. dollar-denominated, taxable, fixed-rate corporate bonds with a rating of BBB or equivalent. This suggests that the fund is exposed to a mix of high-yield and investment-grade debt, providing a balance between income generation and credit risk management. By investing at least 80% of its assets in the component instruments of the underlying index, the fund aims to replicate the performance of the index, while the remaining 20% can be invested in other fixed-income securities.

From a technical analysis perspective, the funds price action indicates a stable trend, with the short-term and long-term moving averages (SMA20, SMA50, and SMA200) converging, suggesting a potential breakout or consolidation phase. The Average True Range (ATR) of 0.03 (0.12%) implies relatively low volatility, which is expected for a bond ETF. Given the current price of $23.25, the proximity to the 52-week high, and the stable moving averages, it is likely that the fund will continue to trade within a narrow range in the short term.

Considering the fundamental data, the funds Assets Under Management (AUM) stand at $558.20 million, indicating a moderate level of investor interest. As the fund approaches its target maturity date in 2025, it is likely that the credit quality of the underlying bonds will become more apparent, potentially leading to a reduction in credit risk and an increase in the funds net asset value. Based on the technical and fundamental analysis, a potential forecast for the fund is that it will continue to trade within a narrow range, potentially breaking out to the upside as the maturity date approaches, driven by a combination of income generation and potential credit risk reduction.

Taking into account the funds characteristics and market conditions, a potential investment strategy could be to hold the ETF until maturity, collecting the regular income distributions, and potentially benefiting from the return of principal. Alternatively, traders could look to capitalize on the expected stability and potential breakout by employing a range-bound trading strategy or a bullish options spread.

IBHE ETF Overview

Market Cap in USD 456m
Category Target Maturity
TER 0.35%
IPO / Inception 2019-05-07

IBHE ETF Ratings

Growth Rating 77.2%
Fundamental -
Dividend Rating 56.1%
Return 12m vs S&P 500 -8.75%
Analyst Rating -

IBHE Dividends

Dividend Yield 12m 5.32%
Yield on Cost 5y 6.86%
Annual Growth 5y 2.91%
Payout Consistency 96.0%
Payout Ratio %

IBHE Growth Ratios

Growth Correlation 3m 99.2%
Growth Correlation 12m 99.8%
Growth Correlation 5y 86.3%
CAGR 5y 8.06%
CAGR/Max DD 3y (Calmar Ratio) 3.41
CAGR/Mean DD 3y (Pain Ratio) 37.30
Sharpe Ratio 12m 0.77
Alpha -0.91
Beta 0.180
Volatility 0.94%
Current Volume 238.8k
Average Volume 20d 92.5k
Stop Loss 22.4 (-3.4%)
Signal 0.86

What is the price of IBHE shares?

As of October 19, 2025, the stock is trading at USD 23.19 with a total of 238,804 shares traded.
Over the past week, the price has changed by +0.06%, over one month by +0.38%, over three months by +1.14% and over the past year by +5.37%.

Is iShares iBonds 2025 Term a good stock to buy?

Yes. Based on ValueRay's Analyses, iShares iBonds 2025 Term (BATS:IBHE) is currently (October 2025) a good stock to buy. It has a ValueRay Growth Rating of 77.22 and therefor a clear technical positive rating according to historical growth.
Based on momentum, paid dividends and discounted-cash-flow analyses, the fair value of IBHE is around 23.70 USD . This means that IBHE is currently overvalued and has a potential downside of 2.2%.

Is IBHE a buy, sell or hold?

iShares iBonds 2025 Term has no consensus analysts rating.

What are the forecasts/targets for the IBHE price?

Issuer Target Up/Down from current
Wallstreet Target Price - -
Analysts Target Price - -
ValueRay Target Price 26 12.1%

Last update: 2025-10-15 03:49

IBHE Fundamental Data Overview

Market Cap USD = 455.6m (455.6m USD * 1.0 USD.USD)
Beta = 0.18
Revenue TTM = 0.0 USD
EBIT TTM = 0.0 USD
EBITDA TTM = 0.0 USD
Long Term Debt = unknown (none)
Short Term Debt = unknown (none)
Debt = unknown
Net Debt = unknown
Enterprise Value = 455.6m USD (455.6m + (null Debt) - (null CCE))
Interest Coverage Ratio = unknown (Ebit TTM 0.0 / Interest Expense TTM 0.0)
FCF Yield = 0.0% (FCF TTM 0.0 / Enterprise Value 455.6m)
FCF Margin = unknown (Revenue TTM is 0 or missing)
Net Margin = unknown
Gross Margin = unknown ((Revenue TTM 0.0 - Cost of Revenue TTM 0.0) / Revenue TTM)
Tobins Q-Ratio = unknown (Enterprise Value 455.6m / Total Assets none)
Interest Expense / Debt = unknown (Interest Expense 0.0 / Debt none)
Taxrate = 21.0% (US default 21%)
NOPAT = 0.0 (EBIT 0.0 * (1 - 21.00%))
Current Ratio = unknown (Total Current Assets none / Total Current Liabilities none)
Debt / Equity = unknown (Debt none)
Debt / EBITDA = unknown (Net Debt none / EBITDA 0.0)
Debt / FCF = unknown (Net Debt none / FCF TTM 0.0)
Total Stockholder Equity = 0.0 (from calculated bookValueOfEquity)
RoA = unknown (Net Income 0.0 / Total Assets none)
RoE = unknown (Net Income TTM 0.0 / Total Stockholder Equity 0.0)
RoCE = unknown (EBIT 0.0 / Capital Employed )
RoIC = unknown (NOPAT 0.0, Invested Capital 0.0, EBIT 0.0)
WACC = 6.68% (E(455.6m)/V(455.6m) * Re(6.68%) + (debt-free company))
Discount Rate = 6.68% (= CAPM, Blume Beta Adj.) -> floored to rf + 0.7*ERP = 8.05%
Fair Price DCF = unknown (Cash Flow 0.0)

Additional Sources for IBHE ETF

News: Wall Street Journal | Benzinga | Yahoo Finance
Tweets: X | Stocktwits
Fund Manager Positions: Dataroma | Stockcircle